Treatment of severe<i>Mycobacterium avium</i>complex pulmonary disease with adjunctive amikacin and clofazimine<i>versus</i>standard regimen alone: a retrospective study

Abstract

<b>Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe <i>M. avium</i> complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients.</b> https://bit.ly/30dxdRj.